MarketCap
Qilian International Holding Group Limited QLI
Facebook
X
Telegram
Qilian International Holding Group Limited Operativer Cashflow | QLI
Operativer Cashflow Jährlich Qilian International Holding Group Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.37 M | 544 K | 312 K | 12.7 M | 345 K | 5.08 M | -580 K | 4.44 M | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 12.7 M | -2.37 M | 2.55 M |
Operativer Cashflow Vierteljährlich Qilian International Holding Group Limited
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -2.37 M | -3.06 M | - | 544 K | 2.56 M | - | 312 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.56 M | -3.06 M | -402 K |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
CNS Pharmaceuticals
CNSP
|
-13.8 M | $ 3.92 | -2.24 % | $ 1.74 M |  USA |
 |
Calithera Biosciences
CALA
|
-43.6 M | - | -10.95 % | $ 876 K | USA |
 |
United Therapeutics Corporation
UTHR
|
1.56 B | $ 562.14 | -0.63 % | $ 24.9 B | USA |
 |
Vericel Corporation
VCEL
|
51.9 M | $ 54.56 | 5.36 % | $ 2.75 B | USA |
 |
Veracyte
VCYT
|
136 M | $ 24.1 | 0.42 % | $ 1.89 B | USA |
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-60.1 M | $ 3.72 | 0.95 % | $ 236 M | USA |
 |
Molecular Templates
MTEM
|
-41.8 M | - | -23.43 % | $ 495 K | USA |
 |
Vanda Pharmaceuticals
VNDA
|
-109 M | $ 3.82 | 6.27 % | $ 225 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-17.6 M | $ 3.22 | 4.21 % | $ 34.3 M | USA |
 |
Viridian Therapeutics
VRDN
|
-276 M | $ 28.47 | -0.28 % | $ 2.9 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-57.6 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
VistaGen Therapeutics
VTGN
|
-66.4 M | $ 0.17 | 3.45 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
-132 M | $ 1.86 | 8.14 % | $ 109 M | USA |
 |
CohBar
CWBR
|
-10.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-5.69 M | - | -1.56 % | $ 12.3 M | USA |
 |
Gossamer Bio
GOSS
|
-171 M | $ 9.77 | 3.72 % | $ 2.23 B | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
GeoVax Labs
GOVX
|
-21.5 M | $ 0.16 | -5.0 % | $ 153 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
-8.13 M | - | -48.37 % | $ 3.71 M | USA |
 |
Annovis Bio
ANVS
|
-25.6 M | $ 0.82 | 23.72 % | $ 16.9 M | USA |
 |
scPharmaceuticals
SCPH
|
-70.5 M | - | - | $ 218 M | USA |
 |
Xeris Pharmaceuticals
XERS
|
28.6 M | $ 15.08 | 15.29 % | $ 2.42 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
-85.6 M | $ 3.15 | 2.61 % | $ 133 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-43 M | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
-59 M | - | 3.77 % | $ 22.4 M | USA |
 |
Zai Lab Limited
ZLAB
|
-151 M | $ 25.49 | 12.77 % | $ 27.9 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
-125 M | $ 1.71 | 2.05 % | $ 123 M | USA |
 |
Zoetis
ZTS
|
2.9 B | $ 79.51 | -3.21 % | $ 35.3 B | USA |
 |
Global Blood Therapeutics
GBT
|
-257 M | - | - | $ 4.62 B | USA |
 |
Inozyme Pharma
INZY
|
-91.9 M | - | - | $ 207 M | USA |
 |
Idera Pharmaceuticals
IDRA
|
-24.5 M | - | -23.04 % | $ 26.6 M | USA |
 |
NanoString Technologies
NSTG
|
-129 M | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
-76.7 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
-294 M | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
-59.6 M | - | - | $ 59.7 M | USA |
 |
GlaxoSmithKline plc
GSK
|
7.74 B | $ 50.28 | -0.27 % | $ 204 B |  Britain |
 |
Sierra Oncology
SRRA
|
-79 M | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-8.19 M | $ 1.03 | 2.95 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-132 M | $ 4.27 | 1.18 % | $ 348 M | USA |
 |
Vaccinex
VCNX
|
-16.2 M | - | -61.37 % | $ 654 K | USA |
 |
ImmuCell Corporation
ICCC
|
2.48 M | $ 9.9 | -0.5 % | $ 89.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-2.6 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Jounce Therapeutics
JNCE
|
-28.9 M | - | - | $ 98.4 M | USA |
 |
Immutep Limited
IMMP
|
-62 M | $ 3.25 | 20.82 % | $ 4.73 B |  Australia |
 |
Verona Pharma plc
VRNA
|
-122 M | - | - | $ 69.7 B | Britain |
 |
Keros Therapeutics
KROS
|
108 M | $ 9.32 | -1.43 % | $ 347 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-13.3 M | $ 7.19 | 2.71 % | $ 110 M | Australia |